Список проголосовавших за комментарий " On The Wires<ul><li>Cellceutix Corporation (<strong>CTIX</strong>) informs shareholders that, next week, the Company will be providing additional detailed data from its ongoing Phase 2a Proof-of-Concept (PoC) study of Brilacidin for the treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).</li><li>Klondex Mines (<strong>KLDX</strong>) disclosed that it has rescheduled its fourth quarter and full year 2016 earnings release and conference call, previously scheduled for Mar 16, 2017, to allow additional time to finalize the accounting adjustments resulting from the initial transition from International Financial Reporting Standards to U.S. Generally Accepted Accounting Principles. Klondex will also reschedule filing its Annual Report on Form 10-K for the fiscal year ended Dec 31, 2016. The revised filing and release date will be Mar 23, 2017. A conference call and webcast will be held the following morning at 10:30 am ET/7:30 am PT.</li><li>On Mar 10, 2017, the Board of Bellerophon Therapeutics (<strong>BLPH</strong>) appointed Megan Schoeps as Principal Financial Officer, effective as of Mar 10, 2017. Schoeps has served as the Controller of the co since Feb 2016. Prior to joining the co, Schoeps served as Manager of Financial Reporting at Actavis from Sept 2013 to May 2015.</li></ul>"